Role of Syn, P63 and TTF-1 in diagnosis and treatment of small cell lung cancer

Abstract

Objective To investigate the value of Syn, P63 and TTF-1 in pathological typing and clinical treatment of small cell lung cancer(SCLC). Methods The clinical data of 70 patients with SCLC confirmed by histopathological examination between January 1st 2011 and December 31th 2013 in Hebei General Hospital were analyzed retrospectively. Pathological sections were subject to HE staining. Immunohistochemistry was used to detect the expression of synaptophysin(Syn), P63 and thyroid transcription factor-1(TTF-1). Then the pathological sections were retyped to distinguish the pure small cell lung cancer (PSCLC) and combined small cell lung cancer (CSCLC). All patients were treated by chemotherapy of EC scheme(Carboplatin+ Etoposide). Patients were followed up, and survival analysis was performed by Kaplan-Meier. Results After pathological examination, one case of poorly differentiated squamous cell carcinoma was excluded. Among the included cases, the positive rates of Syn, P63 and TTF-1 were 97.1%(67/69), 11.6%(8/69) and 88.4%(61/69), respectively. PSCLC and CSCLC accounted for 79.7%(55/69) and 20.3%(14/69), respectively. The effective rate of EC scheme in PSCLC was significantly higher than that in CSCLC(60.0% vs 14.3%; χ2=9.330, P=0.002). The median overall survival durations in PSCLC and CSCLC were 19.9 months and 12.0 months, respectively. The overall survival in PSCLC was significantly higher than that in CSCLC (χ2=9.579, P=0.002). Conclusions The pathological typing of SCLC can benefit from the combined detection of Syn, P63 and TTF-1. The effect of EC scheme on PSCLC is better than that on CSCLC. The prognosis of PSCLC is significantly better than that of CSCLC. Key words: Synaptophysin; P63; Thyroid transcription factor-1; Small cell lung cancer